Philip A. Sharp, Director at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 30,000 shares at $109.00 ($3.3M) on 2015-12-04, disclosed to the SEC on 2015-12-04.
Scheduled sale ($3.3M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| ALNY | SELL | 2018-03-13 | $1.9M | — | Filing → |
| ALNY | SELL | 2017-02-03 | $2.0M | — | Filing → |
| ALNY | SELL | 2017-01-27 | $569K | — | Filing → |